GlassScriptPhysician profile
Ghyass Rizk
NPI 1144267360
$16,396.90
in general payments reported to CMS, 2019-2025
50 companies · $972 in 2025
The $972 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,782 · 2020: $2,103 · 2021: $3,123 · 2022: $2,515 · 2023: $1,908 · 2024: $1,995 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,854 · Education: $20.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,853.93 |
| Education | $20.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $2,428.85 | 2019-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $2,231.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,033.21 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,025.49 | 2019-2023 | Farxiga |
| Esperion Therapeutics, INC. | $749.68 | 2020-2025 | Nexletol |
| Abbvie INC. | $684.79 | 2019-2025 | Ubrelvy, Synthroid |
| Sanofi-Aventis U.S. LLC | $596.49 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $579.73 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $424.02 | 2019-2022 | |
| Amgen INC. | $391.04 | 2019-2025 | Tepezza |
| Beta Bionics, INC. | $383.68 | 2024 | Ilet Bionic Pancreas |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $382.29 | 2019-2023 | Cycloset |
| Idorsia Pharmaceuticals US INC | $337.14 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $307.66 | 2019-2020 | |
| Antares Pharma, INC. | $294.59 | 2019-2025 | Xyosted, Nocdurna, Tlando |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $277.55 | 2019-2025 | Freestyle Libre 3 |
| Shire North American Group INC | $238.24 | 2019 | |
| Xeris Pharmaceuticals, INC. | $219.43 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $214.93 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $196.09 | 2021-2024 | |
| Medtronic, INC. | $187.84 | 2024-2025 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $187.82 | 2019-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $162.95 | 2019-2022 | |
| Horizon Therapeutics Plc | $157.46 | 2022-2023 | Tepezza |
| Corcept Therapeutics | $147.49 | 2021-2025 | Korlym |
| Currax Pharmaceuticals LLC | $144.76 | 2020-2023 | Contrave, Nexlizet, Nexletol |
| Ibsa Pharma INC. | $137.99 | 2019-2021 | |
| Tolmar, INC. | $115.94 | 2023-2025 | Jatenzo |
| Medtronic Minimed, INC. | $112.39 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $109.96 | 2022-2024 | |
| Acella Pharmaceuticals, LLC | $109.75 | 2020-2025 | NP Thyroid 60 |
| Eisai INC. | $98.47 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $98.04 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $74.06 | 2023 | Veozah, Myrbetriq |
| Ascendis Pharma Endocrinology INC | $72.43 | 2024-2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $56.55 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $55.52 | 2020-2024 | Signifor Lar, Isturisa |
| Cequr Corporation | $47.04 | 2024 | Cequr Simplicity |
| Halozyme INC | $42.46 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $37.58 | 2021-2024 | Crysvita |
| Zealand Pharma US, INC. | $34.26 | 2021 | |
| Kvk-Tech, INC. | $33.66 | 2019 | |
| Sequel Med Tech, LLC | $26.56 | 2025 | Twiist |
| Grt US Holding, INC. | $24.31 | 2022 | |
| Amryt Pharma Holdings LTD | $23.06 | 2021 | |
| Becton, Dickinson and Company | $22.71 | 2021 | |
| Embecta Corp. | $20.76 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Sun Pharmaceutical Industries INC. | $20.29 | 2020 | |
| Averitas Pharma INC. | $20.16 | 2024 | Qutenza |
| Amphastar Pharmaceuticals, INC. | $18.57 | 2024 | Baqsimi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghyass Rizk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.